Lessons learned from acute and late scaffold failures in the ABSORB EXTEND trial

EuroIntervention 2014;10:449-457 published online ahead of print January 2014. DOI: 10.4244/EIJV10I4A78

Yuki Ishibashi1, MD, PhD; Yoshinobu Onuma1, MD; Takashi Muramatsu1, MD, PhD; Shimpei Nakatani1, MD; Javaid Iqbal1, MRCP, PhD; Hector M. Garcia-Garcia1, MD, PhD; Antonio L. Bartorelli2, MD; Robert Whitbourn3, MD; Alexander Abizaid4, MD, PhD; Patrick W. Serruys1, MD, PhD; on behalf of the ABSORB EXTEND Investigators

1. Thoraxcenter, Erasmus University Medical Center, Rotterdam, The Netherlands; 2. Centro Cardiologico Monzino, IRCCS, University of Milan, Milan, Italy; 3. St Vincent’s Hospital, Fitzroy, Victoria, Australia; 4. Instituto de Cardiologia Dante Pazzanese,

Aims: Bioresorbable scaffolds are increasingly used in patients with coronary artery disease undergoing percutaneous coronary interventions. ABSORB EXTEND is an ongoing study that will re

Forgot your password?

No account yet? Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

bioresorbable scaffoldscaffold dislodgementscaffold thrombosis

Share on Facebook Share on Twitter Share on Linkedin

Lessons learned from acute and late scaffold failures in the ABSORB EXTEND trial

Read next article

Latest news

Coronary

Valvular disease

Heart failure

Peripheral

Hypertension

Stroke